FibroBiologics (NASDAQ:FBLG) Given Buy Rating at HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of FibroBiologics (NASDAQ:FBLG) in a report issued on Thursday morning,Benzinga reports. HC Wainwright currently has a $12.00 price objective on the stock.

FBLG has been the topic of several other reports. D. Boral Capital restated a “buy” rating and set a $16.00 price objective on shares of FibroBiologics in a research note on Friday, December 27th. Rodman & Renshaw assumed coverage on shares of FibroBiologics in a report on Thursday, December 12th. They set a “buy” rating and a $12.00 target price on the stock. Four analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Buy” and a consensus target price of $13.00.

FibroBiologics Stock Performance

Shares of NASDAQ FBLG opened at $1.29 on Thursday. The stock’s 50 day moving average price is $1.98 and its two-hundred day moving average price is $2.49. FibroBiologics has a 52-week low of $1.08 and a 52-week high of $17.75.

Institutional Investors Weigh In On FibroBiologics

A number of hedge funds have recently added to or reduced their stakes in FBLG. Geode Capital Management LLC grew its position in shares of FibroBiologics by 90.0% during the third quarter. Geode Capital Management LLC now owns 599,760 shares of the company’s stock worth $1,854,000 after acquiring an additional 284,047 shares during the last quarter. Barclays PLC grew its position in FibroBiologics by 363.2% in the 3rd quarter. Barclays PLC now owns 39,958 shares of the company’s stock worth $123,000 after purchasing an additional 31,331 shares during the last quarter. Jane Street Group LLC bought a new position in FibroBiologics in the 3rd quarter worth about $37,000. State Street Corp increased its stake in shares of FibroBiologics by 26.5% in the third quarter. State Street Corp now owns 475,837 shares of the company’s stock valued at $1,470,000 after purchasing an additional 99,789 shares during the period. Finally, The Manufacturers Life Insurance Company bought a new stake in shares of FibroBiologics during the third quarter valued at approximately $32,000.

About FibroBiologics

FibroBiologics, Inc operates as a cell therapy, regenerative medicine company. It is developing a pipeline of treatments and potential cures for chronic diseases using fibroblast cells and fibroblast-derived materials. It holds 150+ U.S. and internationally issued patents/patents pending across various clinical pathways, including disc degeneration, orthopedics, multiple sclerosis, psoriasis, wound healing, reversing organ involution, and cancer.